Deaths and major cardiovascular events in patients with lymphoma: Analysis from a French nationwide hospitalization database.

Bleeding Ischaemic stroke Lymphoma Mortality Myocardial infarction

Journal

Archives of cardiovascular diseases
ISSN: 1875-2128
Titre abrégé: Arch Cardiovasc Dis
Pays: Netherlands
ID NLM: 101465655

Informations de publication

Date de publication:
14 Jun 2024
Historique:
received: 22 01 2024
revised: 17 05 2024
accepted: 21 05 2024
medline: 5 7 2024
pubmed: 5 7 2024
entrez: 4 7 2024
Statut: aheadofprint

Résumé

There are few data assessing the risk of death and cardiovascular events in patients with lymphoma. Using a nationwide hospitalization database, we aimed to address cardiovascular outcomes in patients with lymphoma. From 01 January to 31 December 2013, 3,381,472 adults were hospitalized in French hospitals; 22,544 of these patients had a lymphoma. The outcome analysis (all-cause or cardiovascular death, myocardial infarction, ischaemic stroke, bleedings, new-onset heart failure and new-onset atrial fibrillation) was performed over a 5-year follow-up period. Each patient with lymphoma was matched with a patient without a lymphoma or other cancer (1:1). A competing risk analysis was also performed. After adjustment on all risk factors, cardiovascular and non-cardiovascular co-morbidities, the subdistribution hazard ratios for all-cause death, major bleeding, intracranial bleeding, new-onset heart failure and new-onset atrial fibrillation were higher in patients with lymphoma; conversely, the subdistribution hazard ratios for cardiovascular death, myocardial infarction and ischaemic stroke were lower in patients with lymphoma. In the matched analysis, the risk of all-cause death (subdistribution hazard ratio 1.936, 95% confidence interval 1.881-1.992) and major bleeding (subdistribution hazard ratio 1.117, 95% confidence interval 1.049-1.188) remained higher in patients with lymphoma. In this large nationwide cohort study, patients with lymphoma had a higher incidence of all-cause death and major bleeding.

Sections du résumé

BACKGROUND BACKGROUND
There are few data assessing the risk of death and cardiovascular events in patients with lymphoma.
AIM OBJECTIVE
Using a nationwide hospitalization database, we aimed to address cardiovascular outcomes in patients with lymphoma.
METHODS METHODS
From 01 January to 31 December 2013, 3,381,472 adults were hospitalized in French hospitals; 22,544 of these patients had a lymphoma. The outcome analysis (all-cause or cardiovascular death, myocardial infarction, ischaemic stroke, bleedings, new-onset heart failure and new-onset atrial fibrillation) was performed over a 5-year follow-up period. Each patient with lymphoma was matched with a patient without a lymphoma or other cancer (1:1). A competing risk analysis was also performed.
RESULTS RESULTS
After adjustment on all risk factors, cardiovascular and non-cardiovascular co-morbidities, the subdistribution hazard ratios for all-cause death, major bleeding, intracranial bleeding, new-onset heart failure and new-onset atrial fibrillation were higher in patients with lymphoma; conversely, the subdistribution hazard ratios for cardiovascular death, myocardial infarction and ischaemic stroke were lower in patients with lymphoma. In the matched analysis, the risk of all-cause death (subdistribution hazard ratio 1.936, 95% confidence interval 1.881-1.992) and major bleeding (subdistribution hazard ratio 1.117, 95% confidence interval 1.049-1.188) remained higher in patients with lymphoma.
CONCLUSION CONCLUSIONS
In this large nationwide cohort study, patients with lymphoma had a higher incidence of all-cause death and major bleeding.

Identifiants

pubmed: 38965010
pii: S1875-2136(24)00213-4
doi: 10.1016/j.acvd.2024.05.117
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Masson SAS.

Auteurs

Romain Didier (R)

Cardiology Department, Dijon University Hospital, 21000 Dijon, France.

Amandine Durand (A)

Haematology Department, Dijon University Hospital, 21000 Dijon, France.

Mathieu Boulin (M)

Pharmacy Department, EPICAD LNC-UMR 1231, University of Bourgogne Franche Comté, 14, rue Paul-Gaffarel, 21079 Dijon cedex, France. Electronic address: Mathieu.boulin@chu-dijon.fr.

Denis Caillot (D)

Haematology Department, Dijon University Hospital, 21000 Dijon, France.

Alexandre Bodin (A)

Cardiology Department, Trousseau Hospital, University François Rabelais, 37170 Chambray-lès-Tours, France.

Julien Herbert (J)

Cardiology Department, Trousseau Hospital, University François Rabelais, 37170 Chambray-lès-Tours, France.

Bernard Bonnotte (B)

Haematology Department, Dijon University Hospital, 21000 Dijon, France.

Marianne Zeller (M)

Cardiology Department, Dijon University Hospital, 21000 Dijon, France; PEC2, EA 7460, University of Bourgogne Franche Comté, 21000 Dijon, France.

Yves Cottin (Y)

Cardiology Department, Dijon University Hospital, 21000 Dijon, France.

Laurent Fauchier (L)

Cardiology Department, Trousseau Hospital, University François Rabelais, 37170 Chambray-lès-Tours, France.

Classifications MeSH